Humacyte Announces Presentations by Ukrainian Surgeons on Use of the Human Acellular Vessel™ to Treat Wartime Vascular Trauma at the European Society for Vascular Surgery Annual Meeting
Retrieved on:
Friday, September 23, 2022
Vibration, Trauma, AV, HAV, United States International Programming to Ukraine and Neighboring Regions, U.S. Department of Defense Strategy for Operating in Cyberspace, Infection, Patient, Blast injury, Technology, Injury, Nasdaq, Sokolov, Fresenius Medical Care, Time, Extremities, COVID-19, Sale, Food, Annual general meeting, Company, Priority product, DRS, Military personnel, Annual report, Surgeon, Fast track (FDA), Moyamoya disease, Medicine, SEC, Amputation, Risk, FDA, Intention, European Society for Medical Oncology, Partnership, Forward-looking statement, Priority, Tissue, GLOBE, Hospital, Shoulder, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Terminology, HUMA, Acute stress disorder, Leg, Dentistry, Pharmaceutical industry, Health, Defense
Trauma to the extremities makes up the majority of injuries, primarily vascular injuries to the lower extremities and shoulders.
Key Points:
- Trauma to the extremities makes up the majority of injuries, primarily vascular injuries to the lower extremities and shoulders.
- Shaprynskyi and Sokolov reported that surgeons in Ukraine have utilized the HAV to treat patients with a multitude of wartime injuries.
- The HAV has received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.
- Human Acellular Vessels (HAV) are investigational engineered off-the-shelf replacement vessels initially being developed for vascular repair, reconstruction and replacement.